---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009952"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:25:53.522109+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports Q3 net loss $1.7M; advancing IV selonabant for pediatric cannabis toxicity

## Summary
- Operating expenses $1.9M in Q3 fiscal 2025 vs $1.7M year ago.
- Net loss $1.7M ($0.04/share) vs $1.7M ($0.06/share) in prior year.
- Cash $13.3M plus $3M loan facility; sufficient for planned operations.
- Prioritizing IV selonabant for pediatric CNS depression; Phase 1 SAD study to start Q3 2025.
- FDA confirmed unmet need for pediatric cannabis toxicity treatment; collaboration suggested.

## SEC filing metadata
- accession: 0001641172-25-009952
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000164117225009952/0001641172-25-009952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000164117225009952/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009952
- JSON: https://secwatch.observer/filing/0001641172-25-009952.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.